Release 5

This page is part of the FHIR Specification (v5.0.0: R5 - STU). This is the current published version. For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B

Example MedicinalProductDefinition/equilidem-basics (Narrative)

Biomedical Research and Regulation Work GroupMaturity Level: N/AStandards Status: InformativeCompartments: No defined compartments

This is the narrative for the resource. See also the XML, JSON or Turtle format. This example conforms to the profile MedicinalProductDefinition.

Generated Narrative

Id : equilidem-basics

Identifier : Equilidem25

Combined Pharmaceutical Dose Form : tablet

Indication : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

Legal Status Of Supply : Prescription only medicine

Classification : ATC: B01A

Ingredient :

  • Equilidonium Phosphate
  • Calcium Carbonate

Names

- Product Name
* Equilidem 2.5 mg film-coated tablets

Cross References

- Product
* Link to generic equivalent

Manufacturing/Business Operations

- Manufacturer
* EquiliDrugCo Inc.

 

 

Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.